Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review

Rheumatol Int. 2020 Mar;40(3):489-497. doi: 10.1007/s00296-019-04453-y. Epub 2019 Oct 10.

Abstract

Systemic sclerosis (SSc) is a rare immune-mediated vasculopathy characterized by fibrosis of the skin and internal organs. Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene producing α-galactosidase-A enzyme (α-Gal A) deficiency. Being a systemic disease, cardiac involvement in FD has a high mortality rate due to heart failure and arrhythmia. The coexistence of these two entities has not been reported previously. We describe the case of a female patient with limited SSc (lcSSc), a diagnosis based on the presence of sclerodactyly, Raynaud phenomenon, microvascular involvement, and positive anti-centromere antibodies. On follow-up, she developed chest pain, a second-degree A-V block, and restrictive cardiomyopathy (without cardiovascular risk factors). Although heart involvement is common in these two entities, the abnormal thickening of lateral and inferior wall, the infiltration pattern and the conduction system disorders presented herein are more characteristic in a heterozygous female with a cardiac variant of FD. The diagnosis of FD was confirmed with high globotriaosylsphingosine (Lyso-Gb3) levels and identification of GLA gene mutation. The patient was treated with enzymatic replacement (agalsidase alpha) following mild improvement in ventricular mass at 6th month, without clinical deterioration. The related literature on SSc associated with FD is also reviewed.

Keywords: Autoimmune diseases; Fabry disease; Restrictive cardiomyopathy; Systemic sclerosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Cardiomyopathy, Restrictive / complications*
  • Fabry Disease / complications*
  • Female
  • Humans
  • Middle Aged
  • Scleroderma, Systemic / complications*